Stock RGBP REGEN BIOPHARMA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Regen BioPharma, Inc.

Equities

RGBP

US75886M3007

Market Closed - OTC Markets
Other stock markets
 20:28:29 20/05/2024 BST 		5-day change 1st Jan Change
0.701 USD -0.57% Intraday chart for Regen BioPharma, Inc. +7.02% -26.21%
04-24 Regen BioPharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024 CI
02-09 Regen Biopharma, Inc. Files Provisional Patent Application for Accelerating Hematopoietic Reconstitution After an Insult or Chronic Pathology by Administration of Stem Cell Derived Endothelial Progenitor Cells or Endothelial Cells CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Regen BioPharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024
Regen Biopharma, Inc. Files Provisional Patent Application for Accelerating Hematopoietic Reconstitution After an Insult or Chronic Pathology by Administration of Stem Cell Derived Endothelial Progenitor Cells or Endothelial Cells
Regen BioPharma, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023
Regen BioPharma, Inc. Reports Earnings Results for the Full Year Ended September 30, 2023
Regen BioPharma, Inc. Outlines Future Steps in CAR T Program
Regen BioPharma, Inc Receives Second Phase Confirmatory Data on its Duracar CAR-T Cell Therapy Program
Regen Biopharma, Inc. Expects Second Phase of Confirmatory Study Shortly
Studies on Regen Biopharma, Inc.'s Duracar Indicate Potential Suppression of Autoimmunity, Company Retains Contract Research Organization to Conduct Additional Confirmatory Studies
Regen BioPharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2023
Regen BioPharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2023
Regen BioPharma, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2022
Regen BioPharma, Inc. Announces Board Appointments
Regen BioPharma, Inc. Reports Earnings Results for the Full Year Ended September 30, 2022
Regen BioPharma, Inc. Auditor Raises 'Going Concern' Doubt
Regen BioPharma, Inc. Develops a Non-Exhaustible CAR-T Cell Therapeutic
Regen BioPharma, Inc. Files Provisional Patent on Car-T Cell Capable of Attracting and Educating Naïve T Cells to Kill Cancer
Regen BioPharma, Inc. Files Patent on Paradigm Shifting RNA/DNA-Based Approach to Cancer Immunotherapy
Regen BioPharma, Inc. Begins Experiments Validating Its Proprietary CAR-T Cell Therapy
Regen Biopharma Develops Novel Means of Using Car-T Cell Immunotherapy to Attack Solid Tumors
Regen BioPharma, Inc. Develops Novel Dedifferentiation Approach for Increasing Efficacy of CAR-T Cells to Treat Solid Tumors
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. RGBP Stock
  4. News Regen BioPharma, Inc.
  5. Other languages